Primo N. Lara, Jr., MD Director, UC Davis Comprehensive Cancer Center Professor of Medicine and Executive Associate Dean UC Davis School of Medicine at the Kidney Cancer Association International Meeting, Miami FL
November 15, 2019
Optimal first line therapy for rare kidney cancer variants (non-clear cell):Â Immunotherapy
